<strong>Suicidality common hospitalisation cause for gender-variant young people</strong>
Suicidality or self-harm is a frequent cause of hospital admission among gender variant/diverse young people, report researchers.
Real-world data support early rhGH initiation for SGA children
Observational data confirm that children born small for gestational age achieve the best growth outcomes if they start treatment with recombinant human growth hormone as young as possible.
High-dose semaglutide triggers weight loss in adolescents with obesity
A weekly injection of a high dose of semaglutide results in substantial weight loss among adolescents with obesity, show the STEP TEENS trial findings.
Wide range of neurological issues in paediatric hyperinsulinism/hyperammonaemia syndrome
Neurodevelopmental disorders are frequent and diverse in children with hyperinsulinism/hyperammonaemia syndrome caused by a GLUD1 mutation, a study shows.
Multigene sequencing detects alterations in up to one in six children with ISS
A multigene sequencing panel has successfully identified one or more gene variants in up to one in six children with idiopathic short stature, researchers report in Endocrine Connections.
rhGH therapy does not impact lifetime IGF-1 exposure in SGA children
Years of treatment with recombinant human growth hormone does not increase the cumulative lifetime exposure to insulin-like growth factor-1 above the population average in children born small for gestational age, a study shows.
PEGylated weekly rhGH promising in idiopathic short stature
A weekly injectable PEGylated recombinant human growth hormone gives significantly better height outcomes than no treatment in children with idiopathic short stature, shows a phase 2 trial.
At least 2 years of growth checks after SGA birth ‘mandatory’ to identify short stature risk
Small-for-gestational age children should undergo regular measurements for the first 2 years after birth to help identify individuals who will benefit from recombinant human growth hormone therapy, German researchers advise.
No long-term cardiometabolic consequences of childhood rhGH therapy in adults born SGA
Cardiometabolic risk in people born small for gestational age more than a decade after finishing therapy with recombinant human growth hormone is no higher than in those never given the treatment, a study shows.
Somatropin safety and efficacy confirmed for childhood growth disorders
Analysis of real-world data indicates that the recombinant human growth hormone somatropin is well tolerated and effective for children with a range of growth hormone disorders and other conditions associated with short stature.
